Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
1989-03-07
2002-03-19
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S045000, C514S046000, C514S049000, C514S050000, C514S885000
Reexamination Certificate
active
06358934
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to the use of known chemical compounds and physiologically acceptable salts thereof for the therapeutic and prophylactic control and treatment of the Acquired Immuno Deficiency Syndrome (AIDS), infections by Human Immunodeficiency Virus, hepatitis B virus infections and retrovirus infections for such control and treatment in animals and man.
BACKGROUND OF THE INVENTION
In the late seventies a new disease was reported, which subsequently was referred to as Acquired Immuno Deficiency Syndrome (AIDS). It is now generally accepted that a retrovirus referred to as HIV (Human Immuno Deficiency Virus, formerly known as Human T-cell Lymphotropic Virus (HTLV-III) or Lymphadenopathy Associated Virus (LAV) plays an essential role in the etiology of AIDS.
AIDS is characterized by a profound immunodeficiency due to low numbers of lymphocyte-T-helper cells, which are the targets for HIV (also called HTLV-III/LAV) infection. The profound immunodeficiency in AIDS patients makes these patients highly susceptible to a variety of opportunistic infections of bacterial, fungal, protozoal or viral etiology. The etiological agents among viral opportunistic infections are often found in the herpes virus group, i.e., Herpes simplex virus (HSV), Varicella Zoster virus (VZV), Epstein-Barr virus (EBV) and, especially, cytomegalovirus (CMV). Other retroviruses affecting humans are HTLV-I and II and examples of retroviruses affecting animals are feline leukemia virus and equine infectios anaemia virus.
Hepatitis B virus infections cause severe disease such as acute hepatitis, chronic hepatitis, fulminant hepatitis in a considerable number of persons. It is estimated that there are 200 million patients with chronic hepatitis B infection in the world. A considerable number of the chronic cases progress to liver cirrosis and liver tumours. In some cases the hepatitis infections also take a rapid and severe course as in fulminant B hepatitis with about 90% mortality. At present there is no known effective treatment against hepatitis B infections.
PRIOR ART
The compound 3′-deoxy-3′-fluoro-thymidine is described in Journal f. prakt. Chemie, Vol. 315, 895-900 (1973) as having cytostatic and virustatic activity as selective inhibitor of DNA synthesis. In the same article the synthesis of the compound 2′,3′-dideoxy-3′-fluorocytidine is described.
The compounds 2′,3′-dideoxy-3′-fluoroadenosine and 2′,3′-dideoxy-3′-fluoroguanosine are described in the East-German patents DD 158903 and DD 209197, respectively, as virostatic agents.
REFERENCES:
patent: 3775397 (1973-11-01), Etzold et al.
patent: 4724232 (1988-02-01), Rideout et al.
patent: 0139793 (1980-01-01), None
patent: 158903 (1983-02-01), None
patent: 0158903 (1983-02-01), None
patent: 209197 (1984-04-01), None
patent: 0209197 (1984-04-01), None
patent: 0206497 (1986-12-01), None
patent: 874929 (1987-08-01), None
Kowollik et al., “Ein Never Zugang Zu 1-(2,3-Dideoxy-3-Fluor B-D-ribofurinosyl)-pyrimidinen,” J. Fur. praktische Chemie, vol. 315, No. 5 895-900 (1973).*
Bikbulatov et al., the Chemical Abstracts, 84:25 824 u (1976).*
Cheng et al., “Human Immunodeficiency Virus Reverse Transcriptase,” J. Biol Chem., 262 (5) pp 2187-2189 (1987).*
Herdewijn et al, the Chemical Abstracts, 107: 59403q (1987).*
Herdewijn et al, the Chemical Abstracts, 107: 176403a (1987).*
Mitsuya et al., “Protection of T Cells . . . In Vitro,”Retroviruses In Human Lymphoma/ Leukemia, Japan Sci Soc. Press (1985) pp 277-288.*
Sandström et al., “Antiviral Therapy in AIDS”Drugsv. 34: 372-390 (1987) AIDS PRESS Limited.*
Herdewijn et al., J. Med. Chem. 30:1270-78 (1987).
Summers and Mason, cell, vol. 29:403-415 (1982).
Nordenfelt et al., J. Med. Virol. 22:231-36 (1987).
Vrang et al., Antimicrob. Agent and Chemother. vol. 29, No. 5, pp. 867-872 May 1986.
Langen et al., Acta Biol. Med. Germ., 29:483-494 (1972).
Langen et al., Acta Biol. Med. Germ., 23:759-266 (1969).
Langen et al., Proc. of the 6th Int'l Congress of Chemother. vol. II (1970).
Koshida et al., Inhibition of Human Immuodeficiency Virus in Vitro by combinations of 3′-Azido-3′-deoxythymidine (Zidovudine) and Phosphonoformate (Foscarnet). Antimicrob. Agents and Chemother. In press (1989).
Vrang et al., Reverse Transcriptase from HIV-1, HIV-2, and SIV are Susceptible to Inhibition by Foscarnet and 3′-azido-3′-deoxthymidine triphosphat.
Antimicrob. AGents and Chemother 32:1733-1734 (1988).
Bazin et al., An Analysis of the Inhibition of Replication of HIV and MuLV by Some 3′-blocked Pyrimidine Analogs, Biochem. Pharm. vol. 1989, No. 109-119.
Abstract No. 3007, Abstracts from Book 1, IV Int'l, Conference on AIDS, Stockholm, Jun. 12-16, 1988.
Putkonen et al, Journal of Acquired Immune Deficiency Syndromes, vol. 2, pp. 359-365 (1989).
Wu et al, Antimicrobial Agents and Chemotherapy, vol. 32, No. 12, pp. 1887-1890 (1988).
Oberg, Antiviral Therapy, IV Int'l. Conf. on AIDS, Stockholm 1988, J. Acquired Immune Deficiency Syndromes 1:257-266 (1988).
Lundgren et al., Inhibition of Early Occurence of Viral Antigen in SIV-Infected Macaques as a Measurement of Antiviral Efficacy (Manuscript 1989).
Wu et al., Antimicrob. Agent. and Chemother., vol. 32 No. 12, pp. 1887-1890 (Dec. 1988).
Kowollik et al., “Ein neuer Zugang zu 1-(2′, 3′-Didesoxy-3-fluor-B-D-ribo-furanosyl)-pyrimidinen”, Journal fur praktische Chemie, vol. 315, No. 5: 895-900 (1973).
Chemical Abstracts, vol. 84, No. 25824u (1976), Bikbulativ et al., Vopr. Virusol. 1975, (5), 625-6 (Russ.).
Chemical Abstracts, vol. 102, No. 39565n (1985), Waqar et al., J. Cell. Physiol. 1984, 121 (2), 402-8 (Eng).
Langen et al., “5′-deoxy-5′-fluorothymidine and 3′-deoxy-3′-fluorothymidine Two Thymidine Analogues with Different Points of Attack at the Molecular Level”, Progress in Antimicrobial and Anticancer Chemotherapy: Proceedings of the 6th International Congress of Chemotherapy, vol. II, pp. 394-397 (1970).
Eriksson Bertil Frank Harald
Johansson Karl Nils Gunnar
Oberg Bo Fredrik
Stening Göran Bertil
Medivir AB
Wilson James O.
LandOfFree
Anti-retroviral activity of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anti-retroviral activity of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anti-retroviral activity of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2829265